gastric adenocarcinoma (Cancer)
Information
- Disease name
- gastric adenocarcinoma
- Disease ID
- DOID:3717
- Description
- "A stomach carcinoma that derives_from epithelial cells of glandular origin." [url:http\://en.wikipedia.org/wiki/Adenocarcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04164979 | Active, not recruiting | Phase 2 | Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma | February 4, 2020 | December 30, 2024 |
| NCT04034251 | Active, not recruiting | Phase 2 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | June 9, 2020 | January 30, 2027 |
| NCT03429816 | Active, not recruiting | N/A | OPPOSITE: Outcome Prediction Of Systemic Treatment in Esophagogastric Carcinoma | April 15, 2018 | November 2023 |
| NCT05394740 | Active, not recruiting | Phase 1/Phase 2 | Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | June 6, 2022 | November 2025 |
| NCT03997162 | Active, not recruiting | Early Recovery After Surgery Protocol in Improving Quality of Life in Participants With Stage 0-IIIC Gastric Cancer Undergoing Surgery | October 11, 2018 | December 31, 2024 | |
| NCT05311176 | Active, not recruiting | Phase 2 | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) | August 17, 2022 | July 1, 2026 |
| NCT04523818 | Active, not recruiting | Phase 1 | Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma | August 11, 2020 | December 31, 2028 |
| NCT03399071 | Active, not recruiting | Phase 2 | Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer | July 31, 2017 | August 15, 2025 |
| NCT03959293 | Active, not recruiting | Phase 2 | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | July 17, 2019 | September 27, 2023 |
| NCT01882933 | Active, not recruiting | Phase 3 | D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma | June 2013 | May 2026 |
| NCT03246516 | Active, not recruiting | N/A | Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers | February 1, 2017 | May 2025 |
| NCT05008783 | Active, not recruiting | Phase 3 | A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma | September 17, 2021 | April 14, 2025 |
| NCT03852251 | Active, not recruiting | Phase 1/Phase 2 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma | January 18, 2019 | August 31, 2023 |
| NCT03776487 | Active, not recruiting | Phase 2 | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | January 7, 2019 | December 30, 2026 |
| NCT04499924 | Active, not recruiting | Phase 2/Phase 3 | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer | March 22, 2021 | March 31, 2027 |
| NCT04363801 | Active, not recruiting | Phase 2 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer | July 29, 2020 | December 2025 |
| NCT03195699 | Active, not recruiting | Phase 1 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | November 15, 2017 | December 1, 2024 |
| NCT04344795 | Active, not recruiting | Phase 1 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | May 6, 2020 | October 1, 2024 |
| NCT03092518 | Active, not recruiting | Phase 2 | Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology | June 5, 2017 | October 1, 2027 |
| NCT03686488 | Active, not recruiting | Phase 2 | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | December 20, 2018 | July 1, 2024 |
| NCT04681248 | Available | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | |||
| NCT02443324 | Completed | Phase 1 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | July 29, 2015 | April 12, 2022 |
| NCT02443883 | Completed | Phase 2 | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | July 7, 2015 | June 5, 2019 |
| NCT02448290 | Completed | Phase 2 | Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy | November 12, 2014 | May 17, 2018 |
| NCT02494583 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | July 31, 2015 | June 6, 2022 |
| NCT02495493 | Completed | Phase 2 | S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma | July 2013 | July 2019 |
| NCT02514551 | Completed | Phase 2 | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | October 12, 2015 | December 28, 2018 |
| NCT02545504 | Completed | Phase 3 | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | October 13, 2015 | May 15, 2019 |
| NCT02589496 | Completed | Phase 2 | Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis | March 26, 2016 | December 2021 |
| NCT02628951 | Completed | Phase 2 | Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis | May 26, 2016 | January 2, 2019 |
| NCT02629315 | Completed | N/A | Carnoy's Solution Versus Formalin in Rectal and Gastric Cancer Specimens Following: a Randomized Trial | May 10, 2012 | February 10, 2014 |
| NCT02680990 | Completed | N/A | Resilience and Exercise in Advanced Cancer Treatment | December 2015 | July 2017 |
| NCT02801955 | Completed | Serum and Peritoneal CEA and CA 19-9 for Gastric Adenocarcinoma | April 2015 | March 2017 | |
| NCT02830594 | Completed | Phase 2 | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | October 5, 2016 | January 16, 2024 |
| NCT00062374 | Completed | Phase 2 | Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction | June 2003 | June 2011 |
| NCT00073502 | Completed | Phase 2 | Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer | October 2003 | October 2003 |
| NCT00183911 | Completed | Phase 2 | Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma | November 2003 | April 2007 |
| NCT00352833 | Completed | Phase 2 | Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma | July 2006 | September 2007 |
| NCT00411151 | Completed | Phase 2 | Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer | December 2006 | August 2009 |
| NCT00464893 | Completed | Phase 2 | Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection | April 2007 | April 2013 |
| NCT01129310 | Completed | Phase 2 | First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. | July 2010 | May 18, 2018 |
| NCT01178944 | Completed | Phase 2 | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | September 2010 | November 2015 |
| NCT01336062 | Completed | Phase 1/Phase 2 | Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients | April 2011 | December 2012 |
| NCT01567618 | Completed | Phase 2 | Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer | March 2012 | April 2014 |
| NCT01631552 | Completed | Phase 1/Phase 2 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | December 17, 2012 | August 13, 2020 |
| NCT01757171 | Completed | Phase 2 | Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma | December 2012 | June 2017 |
| NCT01794026 | Completed | Early Phase 1 | Diffusion Weighted Magnetic Resonance Imaging for Preoperative Staging in Gastric Adenocarcinoma Patients | March 2013 | December 2013 |
| NCT01932580 | Completed | Phase 2 | Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma | August 2013 | June 2015 |
| NCT02013154 | Completed | Phase 1 | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab | May 5, 2014 | January 11, 2021 |
| NCT02082210 | Completed | Phase 1/Phase 2 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | March 7, 2014 | January 24, 2018 |
| NCT02128243 | Completed | Phase 2 | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer | September 2014 | October 8, 2020 |
| NCT02287168 | Completed | Early Phase 1 | Effect of Peritoneal Lavage on Surgery-induced Positive Peritoneal Cytology in Gastric Cancer Patients | October 2014 | December 2015 |
| NCT02333188 | Completed | Phase 1 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | December 2014 | December 2017 |
| NCT02335411 | Completed | Phase 2 | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | February 3, 2015 | July 23, 2021 |
| NCT02370498 | Completed | Phase 3 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | May 11, 2015 | June 10, 2021 |
| NCT02864381 | Completed | Phase 2 | Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma | September 1, 2016 | August 23, 2019 |
| NCT02891447 | Completed | Phase 2 | Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer | September 1, 2016 | April 11, 2023 |
| NCT02898077 | Completed | Phase 3 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | March 2, 2017 | April 12, 2021 |
| NCT03024450 | Completed | Trastuzumab Based Therapy in HER2 Positive AGC | January 2012 | December 2016 | |
| NCT03042611 | Completed | Phase 3 | A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer | March 14, 2017 | September 23, 2020 |
| NCT03141034 | Completed | Phase 2 | Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma | November 1, 2017 | April 14, 2023 |
| NCT03196232 | Completed | Phase 2 | Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer | September 13, 2017 | May 29, 2018 |
| NCT03365791 | Completed | Phase 2 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | January 24, 2018 | September 17, 2020 |
| NCT03783936 | Completed | Phase 2 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | January 24, 2019 | August 30, 2022 |
| NCT03802591 | Completed | Phase 3 | A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma | March 28, 2019 | September 22, 2023 |
| NCT03894618 | Completed | Phase 1 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | March 26, 2019 | May 4, 2023 |
| NCT03986502 | Completed | N/A | Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnosed Gastric or Gastroesophageal Junction Adenocarcinoma | January 22, 2021 | October 1, 2022 |
| NCT04047004 | Completed | Phase 1 | Adjuvant PIPAC in Gastric Cancer Patients | March 11, 2020 | October 1, 2022 |
| NCT04074343 | Completed | Phase 1 | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | August 26, 2019 | July 21, 2022 |
| NCT04161781 | Completed | A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer | November 12, 2019 | March 6, 2024 | |
| NCT04483349 | Completed | Assessment of What Patients and Healthcare Providers Value | June 11, 2020 | August 11, 2022 | |
| NCT04517747 | Completed | N/A | Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction | October 15, 2020 | January 20, 2023 |
| NCT06250075 | Completed | N/A | Effects of the Use of Probiotics on the Intestinal Microbiota of Patients With Gastric Cancer | December 12, 2020 | April 26, 2024 |
| NCT06422403 | Not yet recruiting | Phase 2 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers | July 1, 2024 | December 31, 2029 |
| NCT06399757 | Not yet recruiting | Phase 1/Phase 2 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | May 2024 | May 2027 |
| NCT06196697 | Not yet recruiting | Phase 2 | AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer | January 2024 | March 2027 |
| NCT06333314 | Not yet recruiting | Phase 2 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI | May 2024 | September 2030 |
| NCT06118645 | Not yet recruiting | Phase 2 | Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance | November 1, 2023 | August 1, 2026 |
| NCT06454435 | Not yet recruiting | Phase 2 | Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer | June 2024 | June 2027 |
| NCT05296005 | Not yet recruiting | Phase 1 | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers | May 31, 2022 | December 31, 2024 |
| NCT05293535 | Not yet recruiting | Klotho _ LRP-6 _ Gastric Adenocarcinoma | April 1, 2023 | April 1, 2024 | |
| NCT05038098 | Not yet recruiting | Phase 1 | Magnetic Sentinel Lymph Node Mapping in Gastric Cancer | April 30, 2024 | February 2, 2027 |
| NCT04931420 | Not yet recruiting | Phase 2 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels | September 30, 2025 | November 1, 2027 |
| NCT03257163 | Recruiting | Phase 2 | Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer | September 29, 2017 | December 31, 2025 |
| NCT03368963 | Recruiting | Phase 1/Phase 2 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | January 30, 2018 | November 28, 2025 |
| NCT02366819 | Recruiting | Phase 4 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer | December 11, 2014 | June 8, 2025 |
| NCT03715933 | Recruiting | Phase 1 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | October 10, 2018 | July 2026 |
| NCT06266299 | Recruiting | Phase 1 | A Study of KK2269 in Adult Participants With Solid Tumors | January 25, 2024 | December 2027 |
| NCT06289374 | Recruiting | Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery | April 2024 | June 2029 | |
| NCT03809624 | Recruiting | Phase 2 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer | January 30, 2019 | December 2025 |
| NCT03973008 | Recruiting | Phase 3 | Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma | March 11, 2019 | May 31, 2025 |
| NCT06340711 | Recruiting | Phase 2 | Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma | April 25, 2024 | April 2028 |
| NCT06342427 | Recruiting | Stomach Cancer Exosome-based Detection | March 15, 2023 | March 15, 2025 | |
| NCT04047953 | Recruiting | N/A | Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma | September 10, 2019 | November 2026 |
| NCT06353152 | Recruiting | Phase 1 | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma | November 17, 2023 | November 16, 2025 |
| NCT04114136 | Recruiting | Phase 2 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | September 14, 2020 | April 30, 2032 |
| NCT04150640 | Recruiting | Phase 2 | Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma | July 13, 2020 | December 2026 |
| NCT04152499 | Recruiting | Phase 1/Phase 2 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies | February 28, 2020 | December 2025 |
| NCT06370143 | Recruiting | A Study Collecting Health Information to Understand and Prevent Gastric Cancer | April 11, 2024 | April 11, 2036 | |
| NCT04162665 | Recruiting | Phase 2 | Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer | February 14, 2020 | April 30, 2027 |
| NCT04290806 | Recruiting | Registry Platform Gastric/Esophageal Cancer (SAPHIR) | December 4, 2019 | December 31, 2024 | |
| NCT04430738 | Recruiting | Phase 1/Phase 2 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | September 15, 2020 | October 31, 2025 |
| NCT04535414 | Recruiting | Phase 2 | Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers | June 22, 2023 | December 31, 2027 |
| NCT04581473 | Recruiting | Phase 1/Phase 2 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | October 23, 2020 | June 30, 2038 |
| NCT04850729 | Recruiting | Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. | May 25, 2021 | April 1, 2026 | |
| NCT04943406 | Recruiting | Peritoneal Lavage Liquid Biopsy in Patients With Gastric Cancer | May 8, 2020 | May 2025 | |
| NCT04999332 | Recruiting | Phase 2 | Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer | December 10, 2021 | December 31, 2025 |
| NCT05002127 | Recruiting | Phase 2/Phase 3 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | January 15, 2022 | August 2028 |
| NCT05034887 | Recruiting | Phase 2 | Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma | January 31, 2022 | March 31, 2025 |
| NCT05059444 | Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | September 7, 2021 | February 2028 | |
| NCT05076279 | Recruiting | N/A | Safety and Efficacy of Single or Reduced Ports Laparoscopic Gastrectomy for Advanced Gastric Cancer (SPACE-01) | November 15, 2021 | August 31, 2026 |
| NCT05102110 | Recruiting | Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer. | December 1, 2021 | December 1, 2024 | |
| NCT05177133 | Recruiting | Phase 2 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) | November 5, 2021 | November 4, 2029 |
| NCT05235906 | Recruiting | Phase 2 | A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer | August 16, 2022 | March 31, 2025 |
| NCT05319392 | Recruiting | Transcriptomic Signatures in Gastric Adenocarcinoma | August 6, 2021 | October 6, 2025 | |
| NCT05365581 | Recruiting | Phase 1 | A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer | June 7, 2022 | June 30, 2026 |
| NCT05393986 | Recruiting | Phase 1 | Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors | August 4, 2022 | December 30, 2024 |
| NCT05476796 | Recruiting | Phase 2 | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer | June 23, 2023 | January 2027 |
| NCT05482516 | Recruiting | Phase 3 | Evaluating Novel Therapies in ctDNA Positive GI Cancers | March 29, 2023 | December 2028 |
| NCT05567835 | Recruiting | Phase 2 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer | March 6, 2024 | January 2029 |
| NCT05620134 | Recruiting | Phase 1/Phase 2 | Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | October 17, 2022 | February 20, 2026 |
| NCT05705635 | Recruiting | Phase 2 | A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | January 13, 2023 | December 2024 |
| NCT05709574 | Recruiting | Phase 2 | Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer | April 20, 2023 | May 2025 |
| NCT05723718 | Recruiting | MalnutritiOn Assessment With biOelectrical impedaNce Analysis in gastRic Cancer patIentS Undergoing Multimodal trEatment | December 20, 2022 | December 31, 2028 | |
| NCT05753306 | Recruiting | Phase 2 | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | March 16, 2023 | February 1, 2026 |
| NCT05800236 | Recruiting | N/A | Characterisation of the Intratumoral Microbiome in Gastric Adenocarcinoma: to a Personalised Medicine | April 22, 2023 | March 31, 2025 |
| NCT05802056 | Recruiting | Phase 1 | Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis | November 29, 2023 | January 2026 |
| NCT05804331 | Recruiting | The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study | March 14, 2023 | September 14, 2028 | |
| NCT05816863 | Recruiting | Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma | March 1, 2023 | March 1, 2024 | |
| NCT05836584 | Recruiting | Phase 2 | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | December 6, 2023 | October 31, 2027 |
| NCT05902988 | Recruiting | Phase 1/Phase 2 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | October 18, 2023 | June 2026 |
| NCT05977998 | Recruiting | Phase 2 | A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | September 8, 2023 | October 31, 2030 |
| NCT06028737 | Recruiting | Phase 2/Phase 3 | Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | August 25, 2023 | December 2031 |
| NCT06038578 | Recruiting | Phase 2 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | October 4, 2023 | August 31, 2025 |
| NCT06059495 | Recruiting | Phase 2 | Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study | December 18, 2023 | September 1, 2028 |
| NCT06123338 | Recruiting | Phase 2 | A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer | February 1, 2024 | November 30, 2027 |
| NCT03161522 | Recruiting | Phase 2 | Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | February 19, 2018 | December 31, 2026 |
| NCT06206733 | Recruiting | Phase 3 | ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma | January 25, 2024 | December 30, 2028 |
| NCT04111172 | Suspended | Phase 2 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | November 10, 2020 | December 31, 2024 |
| NCT05135845 | Suspended | Phase 2 | Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma | March 22, 2022 | October 2025 |
| NCT04779151 | Suspended | Phase 2 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab | April 7, 2021 | December 2027 |
| NCT04065139 | Suspended | Phase 2 | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study | June 11, 2020 | December 31, 2024 |
| NCT03735290 | Terminated | Phase 1 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer | January 14, 2019 | December 3, 2021 |
| NCT03122548 | Terminated | Phase 2 | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers | August 14, 2017 | January 31, 2018 |
| NCT00667420 | Terminated | Phase 1/Phase 2 | Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma | April 2008 | June 2014 |
| NCT02638909 | Terminated | Phase 2 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | December 2015 | March 29, 2018 |
| NCT02862535 | Terminated | Phase 1 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | September 20, 2016 | October 25, 2019 |
| NCT02485834 | Terminated | Phase 2 | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer | August 2015 | August 2018 |
| NCT01558011 | Terminated | Phase 2 | Using Genetic Polymorphisms to Predict the Efficacy and Toxicity - A Gastric Adenocarcinoma Study | March 2012 | December 2015 |
| NCT04032704 | Terminated | Phase 2 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | October 9, 2019 | November 28, 2023 |
| NCT00848783 | Terminated | Phase 2 | Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers | May 2008 | September 2012 |
| NCT04675983 | Terminated | Phase 3 | A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) | March 10, 2021 | February 12, 2023 |
| NCT04060342 | Terminated | Phase 1 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | August 13, 2019 | April 11, 2022 |
| NCT05687617 | Terminated | Phase 2 | Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma. | December 15, 2022 | March 27, 2024 |
| NCT04089904 | Terminated | Phase 2 | Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma | October 11, 2019 | March 11, 2023 |
| NCT00209079 | Terminated | Phase 2 | Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma | September 2004 | April 2007 |
| NCT04099277 | Terminated | Phase 1 | A Study of LY3435151 in Participants With Solid Tumors | October 28, 2019 | March 5, 2020 |
| NCT04604132 | Terminated | Phase 1/Phase 2 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma | October 6, 2020 | November 21, 2022 |
| NCT02952989 | Terminated | Phase 1 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | February 23, 2017 | June 24, 2019 |
| NCT04682431 | Terminated | Phase 1 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | November 10, 2020 | August 31, 2023 |
| NCT01989858 | Terminated | Phase 3 | ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach) | November 2010 | December 2013 |
| NCT04194463 | Unknown status | N/A | Maintaining Fitness During Neo-adjuvant Chemotherapy for Oesophago-gastric Cancer: a Feasibility Study | February 28, 2019 | June 30, 2020 |
| NCT01552980 | Unknown status | Phase 2 | Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma | March 2012 | February 2014 |
| NCT03042169 | Unknown status | Phase 3 | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer | August 25, 2021 | February 2023 |
| NCT03707639 | Unknown status | Phase 2 | Study of the Combination of Apatinib and POF | November 2018 | November 2020 |
| NCT01379807 | Unknown status | Phase 2 | Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | December 2010 | December 2015 |
| NCT04503967 | Unknown status | Phase 2 | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer | August 1, 2020 | August 1, 2021 |
| NCT03691454 | Unknown status | Phase 2/Phase 3 | Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma. | June 28, 2018 | June 30, 2023 |
| NCT01283217 | Unknown status | Phase 3 | Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer | March 2010 | March 2016 |
| NCT03221400 | Unknown status | Phase 1/Phase 2 | PEN-866 in Patients With Advanced Solid Malignancies | August 29, 2017 | June 2023 |
| NCT04773769 | Unknown status | N/A | Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas | November 7, 2018 | November 2023 |
| NCT04810663 | Unknown status | Outcome of Radiation Therapy in Operated Gastric Cancer | April 1, 2021 | April 1, 2023 | |
| NCT02781285 | Unknown status | Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score | December 2014 | December 2022 | |
| NCT02144727 | Unknown status | Phase 3 | A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer | January 2014 | December 2021 |
| NCT03288350 | Unknown status | Phase 2 | mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA) | February 22, 2018 | December 2023 |
| NCT02007148 | Unknown status | Phase 2 | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer | November 2013 | May 2022 |
| NCT03780608 | Unknown status | Phase 2 | This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO) | July 30, 2019 | December 1, 2023 |
| NCT03631615 | Unknown status | Phase 2 | Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma | August 20, 2018 | December 2020 |
| NCT03788174 | Unknown status | Phase 2 | Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma | February 1, 2019 | December 2020 |
| NCT03244774 | Unknown status | Phase 1 | Phase I Study of the Combination of Apatinib and POF | January 1, 2018 | June 30, 2019 |
| NCT03814759 | Unknown status | Phase 2 | Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma | December 12, 2016 | July 31, 2022 |
| NCT01880632 | Unknown status | Phase 2 | Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma | July 2013 | August 2018 |
| NCT05071755 | Unknown status | Gastrectomy Outcomes in Elderly Patients | November 1, 2021 | March 1, 2022 | |
| NCT01641783 | Unknown status | Phase 2 | Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients | July 2012 | December 2013 |
| NCT01583361 | Unknown status | Phase 3 | SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer | March 2012 | January 2017 |
| NCT02512380 | Unknown status | Phase 3 | Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer | July 2015 | July 2021 |
| NCT02915432 | Unknown status | Phase 1/Phase 2 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | December 2016 | April 30, 2022 |
| NCT04121039 | Unknown status | Phase 2 | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer | December 2019 | December 2023 |
| NCT05249244 | Unknown status | A Real World Study of the Treatment of Gastric Adenocarcinoma With Huachansu | July 1, 2021 | February 28, 2022 | |
| NCT03507998 | Unknown status | Phase 1 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | June 17, 2017 | April 1, 2021 |
| NCT03468244 | Unknown status | N/A | Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms | May 1, 2018 | December 31, 2021 |
| NCT01565109 | Unknown status | Phase 2 | NESC: Neoadjuvant Treatment Of Gastric Adenocarcinoma | March 2009 | March 2018 |
| NCT04190745 | Unknown status | Phase 2 | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study | November 29, 2019 | June 2024 |
| NCT00964080 | Unknown status | Phase 1/Phase 2 | Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma | May 2009 | April 2015 |
| NCT04739202 | Unknown status | Phase 2 | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) | March 19, 2021 | October 26, 2023 |
| NCT04764084 | Unknown status | Phase 1 | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors | April 1, 2021 | February 28, 2023 |
| NCT05056805 | Withdrawn | N/A | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pancreatic or Stomach Cancer Receiving Chemoradiation Therapy Before Surgery, SurgeryStrong Study | March 4, 2021 | September 8, 2022 |
| NCT05001360 | Withdrawn | N/A | Study of FMT Combined With Nivolumab in Gastric Cancer | October 2021 | November 2023 |
| NCT03739801 | Withdrawn | Phase 1/Phase 2 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | April 6, 2020 | April 6, 2023 |
- Disase is a (Disease Ontology)
- DOID:5517
- Cross Reference ID (Disease Ontology)
- NCI:C4004
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:408647009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0278701
- Exact Synonym (Disease Ontology)
- adenocarcinoma of stomach
- Exact Synonym (Disease Ontology)
- stomach adenocarcinoma